Improving HIV treatment for children and adolescents using Dolutegravir
Addressing Research Gaps to Optimize Dolutegravir-based ART in Children and Adolescents
This study is looking to make HIV treatment better for kids and teens by figuring out the best doses and safety of a medicine called Dolutegravir, especially for those living in low- and middle-income countries.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-11007541 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of Dolutegravir-based antiretroviral therapy (ART) for children and adolescents living with HIV. It aims to address existing gaps in knowledge regarding the appropriate dosing and safety of Dolutegravir in younger populations, particularly in low- and middle-income countries. By investigating the unique needs of children and adolescents, the study seeks to optimize treatment regimens that are more tolerable and effective, ultimately improving health outcomes. The research will involve collecting data on drug interactions and the impact of weight-based dosing in pediatric patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include children and adolescents aged 0 to 21 years who are living with HIV and are currently receiving or are eligible for antiretroviral therapy.
Not a fit: Patients who are not living with HIV or those who are older than 21 years may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and better health outcomes for children and adolescents living with HIV.
How similar studies have performed: Previous research has shown promising results with Dolutegravir in adult populations, but this specific approach in pediatric settings is still being explored.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Kwara, Awewura Jacob — University of Florida
- Study coordinator: Kwara, Awewura Jacob
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.